期刊文献+

DPP-4抑制剂对2型糖尿病心血管并发症危险因素的护理干预

原文传递
导出
摘要 目的探讨DPP-4抑制剂对2型糖尿病心血管并发症危险因素的护理干预措施及作用。方法选择2016年1月~2017年10月我院收治的112例2型糖尿病患者,分别对其进行DPP-4抑制剂治疗,依照护理方式的不同将其分为对照组(n=56)与试验组(n=56),对照组施以常规护理模式,试验组施以整体护理模式,观察两组患者护理前后的各项临床指标与心血管事件发生率及残余血管风险情况。结果护理前,两组患者的各项临床指标无显著差异(P>0.05);护理后,试验组的各项临床指标明显优于对照组,其心血管事件发生率及残余血管风险发生率明显低于对照组,差异显著(P<0.05)。结论 DPP-4抑制剂治疗联合整体护理模式能够有效降低2型糖尿病心血管并发症的发生率,具有显著的临床作用与较高的临床推广价值。
出处 《首都食品与医药》 2019年第6期174-175,共2页 Capital Food Medicine
基金 DPP-4抑制剂对新诊断2型糖尿病患者骨代谢及血清Cathe K的影响
  • 相关文献

二级参考文献99

  • 1Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibi- tion : beyond GLP-1. Vascul Phannaco1,2011,55 : 10-16.
  • 2Monami M, Ahr6n B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk:a meta-analysis of randomized clinical trials. Diabetes Obes Metab ,2013, 1 5 : 112-120.
  • 3Frederich R, Alexander JH, Fiedorek FT, et al. A systematic as- sessment of cardiovascular outcomes in the saxagliptin drug de- velopment program for type 2 diabetes. Postgrad Med ,2010,122 :16-27.
  • 4Johansen OE, Neubacher D,van Eynatten M,et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus : a prc-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol,2012,11:3.
  • 5Huisamen B, Genis A, Marais E, et at. Pre-treatment with a DPP4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Tber,2011,25:13-20.
  • 6Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct size-limit- ing effect of sitagliptin is PKA-dependent,whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol,2010,298 :H1454-H1465.
  • 7Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharma- cological inhibition of dipeptidyl peptidase-4 improves cardiovas- cular outcomes after myocardial infarction in mice. Diabetes, 2010,59 : 1063-1073.
  • 8Gomez N,Touihri K, Matheeussen V, et at. Dipeptidyl peptidase 1V inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail,2012,14 : 14-21.
  • 9Yin M,SilIj6 HH,Meissner M,et al. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial in- farction heart failure. Cardiovasc Diabeto1,2011,10 : 85.
  • 10Read PA, Khan FZ, Hock PM, et at. DPP-4 inhibition by sitaglip- tin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ C ardiovasc Imaging, 2010,3 : 195 -201.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部